IMMUNITYBIO, INC. Secured Long-term Debt, Noncurrent
IMMUNITYBIO, INC. (IBRX) had Secured Long-term Debt, Noncurrent of $415.09 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation › Long-Term Debt, Excluding Current Maturities
us-gaap:SecuredLongTermDebt · last filed 2026-08-04
- 2026-06-30: Secured Long-term Debt, Noncurrent $415.09M.
- 2026-03-31: Secured Long-term Debt, Noncurrent $404.30M.
- 2025-12-31: Secured Long-term Debt, Noncurrent $324.62M.
- 2025-09-30: Secured Long-term Debt, Noncurrent $316.14M.
| Period end | Secured Long-term Debt, Noncurrent |
|---|---|
| 2026-06-30 | $415.09M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $404.30M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $324.62M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $316.14M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $307.05M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $296.29M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $284.40M 10-K · filed 2026-02-23 |
| 2024-09-30 | $273.66M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $263.34M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $163.42M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $155.41M 10-K · filed 2025-03-03 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |